A Novel Fusion of TPR and ALK in Lung Adenocarcinoma
- Authors
- Choi, YL[Choi, Yoon-La]; Lira, ME[Lira, Maruja E.]; Hong, M[Hong, Mineui]; Kim, RN[Kim, Ryong Nam]; Choi, SJ[Choi, So-Jung]; Song, JY[Song, Ji-Young]; Pandy, K[Pandy, Kinnari]; Mann, DL[Mann, Derrick L.]; Stahl, JA[Stahl, Joshua A.]; Peckham, HE[Peckham, Heather E.]; Zheng, ZL[Zheng, Zongli]; Han, J[Han, Joungho]; Mao, M[Mao, Mao]; Kim, J[Kim, Jhingook]
- Issue Date
- Apr-2014
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Keywords
- Lung cancer; ALK; TPR; Translocation
- Citation
- JOURNAL OF THORACIC ONCOLOGY, v.9, no.4, pp.563 - 566
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THORACIC ONCOLOGY
- Volume
- 9
- Number
- 4
- Start Page
- 563
- End Page
- 566
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/53495
- DOI
- 10.1097/JTO.0000000000000093
- ISSN
- 1556-0864
- Abstract
- Introduction: Anaplastic lymphoma kinase (ALK) fusion is the most common mechanism for overexpression and activation in non-small-cell lung carcinoma. Several fusion partners of ALK have been reported, including echinoderm microtubule-associated protein-like 4, TRK-fused gene, kinesin family member 5B, kinesin light chain 1 (KLC1), protein tyrosine phosphatase and nonreceptor type 3, and huntingtin interacting protein 1 (HIP1). Methods and Results: A 60-year-old Korean man had a lung mass which was a poorly differentiated adenocarcinoma with ALK overexpression. By using an Anchored Multiplex polymerase chain reaction assay and sequencing, we found that tumor had a novel translocated promoter region (TPR)-ALK fusion. The fusion transcript was generated from an intact, in-frame fusion of TPR exon 15 and ALK exon 20 (t(1;2)(q31.1;p23)). The TPR-ALK fusion encodes a predicted protein of 1192 amino acids with a coiled-coil domain encoded by the 5'-2(nd) of the TPR and juxtamembrane and kinase domains encoded by the 3'-end of the ALK. Conclusions: The novel fusion gene and its protein TRP-ALK, harboring coiled-coil and kinase domains, could possess transforming potential and responses to treatment with ALK inhibitors. This case is the first report of TPR-ALK fusion transcript in clinical tumor samples and could provide a novel diagnostic and therapeutic candidate target for patients with cancer, including non-small-cell lung carcinoma.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.